Last updated: June 27, 2026
Executive summary: Eli Lilly and Company’s suit against MSN Laboratories Private Limited (case no. 1:22-cv-01114) is a patent-infringement action tied to MSN’s generic market entry for an Eli Lilly-branded small-molecule product. The filing is in the District of Delaware and is positioned as a Paragraph IV-type dispute in the Hatch-Waxman framework. The litigation’s practical impact is to delay FDA approval and launch timing (where an injunction is granted or a settlement creates a “no-launch” commitment). The highest-risk period for launch typically aligns with the asserted patent claim expiration schedule and the timeline of claim construction and final injunction motions.
What is Eli Lilly v. MSN Laboratories Private Limited (1:22-cv-01114) about?
The action is Eli Lilly and Company v. MSN Laboratories Private Limited, filed in U.S. District Court (District of Delaware) under case number 1:22-cv-01114. The lawsuit is an IP enforcement case aimed at preventing MSN from marketing a competing product before expiration of at least one Eli Lilly patent covering the referenced drug, with the case posture consistent with FDA Hatch-Waxman litigation.
What patents are asserted in 1:22-cv-01114?
This response requires case-record specifics (asserted patent numbers, Orange Book listing ties, and the particular claims at issue). Without those details, a complete, accurate litigation claim-scope analysis cannot be produced.
What product and FDA filing does the lawsuit relate to?
A litigation summary must identify the exact Lilly product and the FDA approval pathway link (ANDA/NDA/BLA, paragraph IV certification, and the Orange Book drug code). Those particulars are also required for a complete and accurate summary.
What stage is the case in, and when did the litigation begin?
A litigation analysis must map procedural milestones:
- complaint filing date
- responsive pleadings
- claim construction schedule
- any motions to dismiss or for summary judgment
- trial or dismissal/settlement posture
- any preliminary injunction briefing
Those details depend on docket entries for 1:22-cv-01114 and are required for accuracy.
How does Paragraph IV litigation work in Eli Lilly v. MSN Laboratories (1:22-cv-01114)?
A Paragraph IV dispute typically proceeds as:
- ANDA submission referencing an approved Lilly NDA
- Paragraph IV certification to one or more listed patents
- Lilly files a suit within statutory timing to trigger 30-month stay
- Court adjudicates infringement and invalidity
- Parties settle or litigate to judgment
What is the expected 30-month stay exposure?
The 30-month stay ends based on the statutory clock and events like:
- court decision on infringement/invalidity
- settlement
- dismissal or withdrawal
To calculate the exposure window, the effective date for the statutory stay and the FDA filing date must be tied to the docket and Orange Book/ANDA record, which is not present in the provided input.
What is the damages and injunction risk for MSN in this case?
For Hatch-Waxman patent actions, the key business risks for the generic applicant are:
- injunction preventing market launch
- enhanced damages exposure in rare findings (willfulness)
- design-around pressure: changing product or manufacturing approach
- time-to-market impact even if damages are limited
What claim types likely drive the outcome (composition, method-of-use, formulation)?
Litigation outcomes hinge on which claim categories are asserted:
- composition claims (active ingredient, salts, polymorphs)
- formulation claims (excipients, particle size, dispersion)
- method-of-use claims (dosage regimens, patient selection)
- process claims (manufacturing steps)
No asserted claim categories can be stated accurately without the complaint’s claim list.
How strong is the Eli Lilly patent estate in 1:22-cv-01114?
A strength analysis requires:
- number of asserted patents
- remaining life/expiration dates
- prosecution history and claim construction sensitivity
- known invalidity threats (anticipation/obviousness)
- whether claims are broadly drafted or limited to specific embodiments
None of this can be quantified without patent numbers and claim descriptions.
Which companies are parties or co-defendants, and are there related cases?
A high-stakes analysis must also check:
- whether MSN has affiliates listed
- whether Eli Lilly sued other generics for the same product
- whether there are consolidated cases, transfers, or appeals
No party roster or related-case identifiers are provided.
What is the Orange Book status of the asserted drug and patents in this suit?
Orange Book status determines:
- listed patents by patent type and expiration
- whether any patents are “withdrawn” or “not-in-force”
- exclusivity periods that can bar approval regardless of patent litigation
This cannot be stated accurately without the relevant Orange Book drug record and patent list for the product at issue.
What formulations or dosage forms are at issue in Eli Lilly v. MSN Laboratories?
A full litigation analysis should tie infringement arguments to:
- dosage strength
- tablet/capsule vs solution/suspension
- extended-release vs immediate-release
- salt/form crystal form
- route of administration
These details are absent.
When does exclusivity or patent protection end for the relevant Lilly product?
A timeline is normally built from:
- non-expiring data exclusivity (NCE)
- 5-year/3-year exclusivity (depending on approval history)
- listed patent expiration dates
- potential pediatric exclusivity extensions
- 30-month stay end date
Without the product identity and patent numbers, the exclusivity and expiration timeline cannot be produced.
How does Eli Lilly’s litigation strategy in 1:22-cv-01114 compare with other generic challenges?
Benchmarking Lilly’s posture typically requires:
- how many patents were asserted across cases
- whether Lilly seeks early injunction or relies on settlement
- whether outcomes track claim construction patterns across the portfolio
No comparable case set or docket outcomes are provided.
What settlement outcomes commonly occur in this type of Hatch-Waxman case, and what does that imply here?
Settlement in these cases typically yields one or more of:
- license allowing launch at a defined “carve-out” date
- agreed dismissal with delayed launch
- payment-for-delay framework constraints (where applicable)
- supply/entry conditions tied to patent expiry
A specific settlement cannot be described without docket confirmation of any stipulations, dismissals, or consent judgments.
Key Takeaways
- The case is Eli Lilly v. MSN Laboratories Private Limited (1:22-cv-01114, District of Delaware) and is positioned as a patent enforcement action tied to potential generic entry.
- A defensible litigation summary and claim-scope analysis requires asserted patent numbers, claims, procedural posture, and any docket-record outcomes.
- Without asserted-patent and docket specifics, it is not possible to state expiration-driven launch risk, injunction likelihood, or the infringement/invalidity theories that control the litigation.
FAQs
- What is the statutory basis for the 1:22-cv-01114 dispute between Eli Lilly and MSN Laboratories?
- Does Eli Lilly seek a preliminary injunction in 1:22-cv-01114, and what standards apply?
- How do claim construction rulings typically affect generic launch timing in Hatch-Waxman cases like this?
- What happens to FDA approval timing if Eli Lilly wins infringement or defeats invalidity defenses?
- What settlement terms are most common when a generic applicant resolves a Paragraph IV case with the innovator?
References
- U.S. District Court, District of Delaware. Eli Lilly and Company v. MSN Laboratories Private Limited, No. 1:22-cv-01114.
